Changes to UK’s VPAG: Non-submissions should be a key metric of impact
Leela Barham argues that, whatever people think of the changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to HTA agency NICE, given the focus on increasing access to new medicines for patients.